MAP2K1 and thyroid cancer: On the other hand, we treated BRAFV600E-mutated thyroid cancer lines BCPAP and 8505C with 1 μM PLX4720 (a selective inhibitor of BRAFV600E) alone or in combination with 500 nM GSK1120212 (MEK1/2 inhibitor) for 24 h.